No clamps, no stitches: new robotic surgery aims to save more kidney function
NCT ID NCT06722807
First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times
Summary
This study tests a new robotic surgery technique for kidney cancer that avoids clamping blood vessels and using stitches to close the kidney. The goal is to preserve as much kidney function as possible and reduce the risk of long-term kidney disease. About 59 adults with small kidney tumors (up to 7 cm) will undergo the procedure, and researchers will check safety, tumor removal success, and kidney function afterward.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- clampless, sutureless robotic partial nephrectomy (surgical procedure)
- What this could lead to
- If successful, this technique could become a safer, kidney-sparing surgery option for many patients with small kidney tumors, reducing long-term kidney damage.
- What could go wrong
- This is a small, early-phase study (59 people) testing safety and feasibility. The technique may not work for all tumor types or locations, and risks like bleeding or incomplete tumor removal remain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 59 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults ≥ 18 years of age. * Patients undergoing partial nephrectomy for renal masses ≤ 7 cm * Subjects must not have more than one active malignancy at the time of enrollment. (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \[as determined by the treating physician or approved by the Principal Investigator\] may be included). * A clinical diagnosis consistent with renal cell carcinoma, cT1-3 N0 M0 without renal vein thrombus. * Adequate laboratory test results, including: 1. Platelets \> 50,000/µL 2. Hemoglobin \> 9.0 g/dL * Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures. * Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 2 weeks after surgery to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. * Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 2 weeks following surgery. Exclusion Criteria: * Bleeding disorder (any congenital bleeding diathesis) * Liver dysfunction with end stage liver disease as determined by the treating investigator * Presence of renal vein thrombus * End stage renal disease (eGFR \< 15 using Cockcroft-gault formula or receiving renal replacement therapy (i.e. dialysis)) * Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 2 weeks after surgery. * Subjects who are confirmed to be pregnant or breastfeeding. * History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. * Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Renal cell carcinoma (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Florida
Gainesville, Florida, 32610, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer aims to spot kidney cancer with sharper eyes
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- Cell therapy combo aims to boost kidney cancer treatment
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?
- Engineered immune cells take on kidney cancer in first human test